347 related articles for article (PubMed ID: 21138954)
41. Current treatment options in triple negative breast cancer.
Rodler E; Korde L; Gralow J
Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
[TBL] [Abstract][Full Text] [Related]
42. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
43. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
44. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
Ganesan S; Karantza V; Oza J; Toppmeyer D
Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
[TBL] [Abstract][Full Text] [Related]
45. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
46. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
47. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
48. Triple-negative breast cancer.
Bartsch R; Ziebermayr R; Zielinski CC; Steger GG
Wien Med Wochenschr; 2010 Apr; 160(7-8):174-81. PubMed ID: 20473728
[TBL] [Abstract][Full Text] [Related]
49. Triple-negative breast cancer: making the most of a misnomer.
McCarthy N; Mitchell G; Bilous M; Wilcken N; Lindeman GJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):145-55. PubMed ID: 22524573
[TBL] [Abstract][Full Text] [Related]
50. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
51. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
52. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
Linn SC; Van 't Veer LJ
Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
[TBL] [Abstract][Full Text] [Related]
53. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
54. Targeting triple negative breast cancer: is p53 the answer?
Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
[TBL] [Abstract][Full Text] [Related]
55. Triple-negative breast cancer: unique biology and its management.
Maegawa RO; Tang SC
Cancer Invest; 2010 Oct; 28(8):878-83. PubMed ID: 20839950
[TBL] [Abstract][Full Text] [Related]
56. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
57. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
58. Clinical trials in triple negative breast cancer.
Reeder-Hayes KE; Carey LA; Sikov WM
Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
[TBL] [Abstract][Full Text] [Related]
59. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
60. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
